Protocols
29 protocol(s) meet the specified criteria
Disease Site: Bladder
Protocol No.TitleStatus
16-2171Multi-Institutional Study to Evaluate DNA Methylation Markers For Detection of Primary Bladder Cancers in Urine Samples From a Cohort of Patients with Hematuria.Open
AMC-095A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors and a Cohort of HIV-Associated Classical Hodgkin LymphomaOpen
APEC1621SCNCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)Open
ASG-22CE-13-2A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and Other Malignant Solid Tumors that Express Nectin-4Open
CA209-274A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial CarcinomaOpen
ETCTN9767-CIRBAn Open Label, Multicenter, Single arm Phase II study to evaluate the Activity and Tolerability of the novel mTOR Inhibitor, MLN0128 (TAK-228), in patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the urothelial tract whose tumors harbor a TSC1 and/or a TSC2 mutation.Open
ETCTN9947-CIRBA Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial CarcinomaOpen
GO30140An Open-Label, Multicenter Phase Ib Study of the Safety and Tolerability of Atezolizumab (ANTI-PD L1 Antibody) Administered in combination with Bevacizumab and/or other Treatments in Patients with Solid Tumors.Open
GU14-182A Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-line Chemotherapy in Patients with Metastatic Urothelial CancerOpen
GU15-217UC-GENOME: Urothelial Cancer-GENOnomic analysis to iMprove patient outcomes and rEsearchOpen
INCAGN1876-201A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination with Immune therapies in Subjects with Advanced or Metastatic MalignanciesOpen
INCB-54828-201A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically unresectable Urothelial Carcinoma Harboring FGF/FGFR AlterationsOpen
LCCC1206PORCH: A Registry of Prospective Outcomes of Radical Cystectomy with or without ChemotherapyOpen
LCCC1517Identifying High-Priority Patient-Centered Outcomes in the Postoperative Cystectomy PeriodOpen
LCCC1520Phase 2 study of pembrolizumab in combination with gemcitabine and cisplatin as neoadjuvant therapy prior to radical cystectomy in patients with MIBCOpen
LCCC1527Evaluation of the Chemotherapy Toxicity Risk Score for Treatment Decision in Elderly Patients with Advanced Solid CancerOpen
LCCC1623Interviewing cancer patients and caregivers about using symptom questionnaires to improve quality of cancer careOpen
LCCC1635Pilot study evaluating the microbiome in bladder and prostate cancer patientsOpen
LCCC1636Using PROMIS as part of routine clinical care for racially diverse prostate and bladder cancer patientsOpen
LCCC1734Adaptation of the Parenting Concerns Questionnaire for Patients with IllnessOpen
MCC-16962A Phase I Trial of Dose Escalation of Metformin in Combination with Vincristine, Irinotecan, and Temozolomide in Children with Relapsed or Refractory Solid TumorsOpen
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
NC-6300-001A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue SarcomaOpen
NYU-PCC-S15-00220A Phase II Trial of MK3475 in Combination with Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder Sparing Treatment for Muscle-Invasive Urothelial Cancer of the BladderOpen
PCRC-14-07Caregiver-­‐guided pain management training in palliative careOpen
RAD-IFN-CS-003A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN® (rAd-IFN/Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive, Non-Muscle Invasive Bladder Cancer (NMIBC).Open
S1602A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal Bcg Before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder CancerOpen
TC-UT-03-PA Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of MitoGel™ on Ablation of Upper Urinary Tract Urothelial CarcinomaOpen
VANDERBILT001A prospective multi-institutional randomized trial evaluating observation versus immediate surgery in the management of low grade noninvasive bladder cancerOpen